HRV VLPs for Cross-Neutralizing Antibodies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines fail to provide effective protection against the large number of human rhinovirus serotypes, as they do not induce a protective response that can cross-neutralize multiple serotypes, making it challenging to develop a vaccine that can protect against multiple HRV infections.
Innovation Solution
The development of virus-like particles (VLPs) comprising human rhinovirus capsid proteins VP0, VP1, and VP3, or VP1, VP2, and VP4, expressed as fusion proteins with SUMO sequences, which are used to induce an immune response and provide cross-neutralizing antibodies against multiple serotypes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional vaccines targeting single serotypes are used, then specific protection against that serotype is achieved, but protection against other serotypes is not provided
Solution Approach 1:
The patent employs conserved peptide sequences from multiple HRV serotypes (including clades A, B, and C) to create a vaccine composition that provides universal protection across different serotypes. The selected peptides from VP1, VP2, VP3, and VP4 proteins share high sequence identity across serotypes, enabling a single vaccine formulation to elicit cross-neutralizing antibodies against multiple HRV strains simultaneously.
Solution Approach 2:
The vaccine composition combines multiple conserved peptide sequences from different viral proteins (VP1, VP2, VP3, VP4) and different serotypes into a composite formulation. This composite approach integrates epitopes from various viral components to generate a broader immune response that covers multiple serotypes, overcoming the limitation of single-serotype vaccines.
2Adaptability or versatility
If a vaccine targets multiple serotypes, then cross-protection is improved, but the complexity of identifying conserved regions across serotypes increases
Solution Approach 1:
The patent divides the HRV capsid proteins into specific segmented regions (peptides of 6-20 amino acids) that exhibit conservation across serotypes. By focusing on discrete peptide segments from VP1, VP2, VP3, and VP4 proteins rather than entire proteins, the design process becomes more manageable while maintaining cross-serotype efficacy.
Solution Approach 2:
The vaccine design targets specific local regions (conserved peptide sequences) within the viral proteins that maintain high sequence identity across different serotypes. These localized conserved epitopes are selected based on their structural importance and conservation patterns, allowing focused vaccine development on critical regions rather than entire protein structures.
3Reliability
If conserved peptides from multiple proteins are used, then cross-neutralizing activity is improved, but the manufacturing complexity increases
Solution Approach 1:
The patent employs synthetic peptide sequences rather than requiring production of entire viral proteins or live attenuated viruses. These short conserved peptide sequences can be chemically synthesized using standard peptide synthesis methods, eliminating the need for complex cell culture systems, viral propagation, and extensive purification processes required for traditional vaccine platforms.
Data Source
Figure 1
Figure 2
Figure 3~4
AI summary
The present invention relates HRV VLPs and methods of making HRV VLPs.